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Introduction
Lectins are known to provide molecular recognition and play key roles in diverse biological processes. As such, they provide tools for deciphering the biological information stored in the sugar code (Reuter & Gabius, 1999) . Today, lectins are de®ned as proteins that possess at least one non-catalytic domain that speci®cally and reversibly binds a monosaccharide or oligosaccharide (Peumans & Van Damme, 1995) . The lectin structures investigated so far are simply built up of -sheet arrangements and folds such as the -prism, -barrel, -sandwich and -trefoil structures (Wright, 1997) . Lectins are also categorized into families according to their sugar speci®city. Monosaccharides are bound with dissociation constants in the 0.1± 1.0 mM range. In order to increase the overall af®nity, distinct multivalences are introduced at lectin subunits or subsites (Rini, 1995) .
Mistletoe lectin I (ML-I) is a galactose-speci®c lectin from Viscum album consisting of two chains. While the lectin activity and speci®-city are located in the B-chain, the A-chain has rRNA N-glycosidase activity and irreversibly inhibits protein biosynthesis by cleavage at A 4324 located in the conserved GAGA loop of 28S rRNA (Endo et al., 1988) . By virtue of this activity, ML-I belongs to the class of ribosome-inactivating proteins (RIPs). The fusion of the toxic component with a galactose-speci®c lectin subunit supports ef®cient uptake into the target cells. In this way, the lectin subunit magni®es the RIP toxicity, as judged by comparison of IC 50 values of RIPs of type II with those of type I, which lack lectin activity (Barbieri et al., 1993) .
ML-I and ricin are homologous RIPs and share similar structure and mechanism. However, the toxins differ in their speci®city towards galactose-terminated complex oligosaccharides on the cell surface (Franz, 1986) . As a result, the two RIPs occupy different binding sites on the cell surface, which partly explains the difference in toxicity, as the activity of the A-chain is approximately the same in both RIPs (Stirpe et al., 1980) . A crucial step in toxicity is the effectiveness of translocation through the cell membrane. The uptake of ricin occurs in the form of the inactive heterodimer (Mohanraj & Ramakrishnan, 1995) , whereas the ML-I subunits are separated on the cell membrane prior to translocation (Agapov et al., 1999) . In spite of its toxicity, ML-I is today applied in the treatment of human cancer in doses of $1 ng per kilogram body weight , which cause immunomodulatory, antimetastatic and antitumoral effects in animal studies and in humans. The lectin component of ML-I is responsible for the immunomodulation, as chemical labelling of the lectin localizes it on the surface of peripheral and intratumoral monocytes . Furthermore, it has been shown that MLB causes Ca 2+ in¯ux in Jurkat cells through interaction with surface glycoprotein receptors and is responsible for early T-cell activation (Walzel et al., 2001) .
The available X-ray structures of galactose-speci®c lectins in complex with their ligands, those of Erythrina corallodendron lectin (Elgavish & Shaanan, 1998) and peanut lectin (Banerjee et al., 1996) , have established the mode of sugar binding and emphasized the importance of recognition and binding through the 4 H -and 3 H -hydroxyl groups of galactose. Af®nity studies against galactose and lactose and the recently published 3.0 A Ê low-resolution structure of ML-I in complex with galactose (Niwa et al., 2003) con®rmed the importance of galactose monosaccharide binding through the 4 H -and 3 H -hydroxyl groups (Lee et al., 1994) . Additional structural elements enhancing galactose speci®city are achieved through van der Waals interactions of the sugar ring with aromatic side chains.
In order to gain a deeper and more detailed understanding of sugar speci®city, we present and compare the modes of galactose and lactose binding to ML-I at 2.3 A Ê and compare the binding geometries to related RIPs of type II with higher and lower toxic potential than ML-I. Furthermore, we outline distinct structural features that are relevant for galactose binding and thereby for modulating toxicity. Finally, a potential third galactose-binding site is described and discussed relative to the architectures of galactose-binding sites I and II.
Material and methods

Crystallization
Mistletoe lectin I was puri®ed for crystallization experiments following previously described procedures (Franz et al., 1981; Krauspenhaar et al., 1999 Krauspenhaar et al., , 2002 ) and concentrated to 10 mg ml À1 in 0.2 M glycine±HCl buffer pH 2.5 for crystallization setups. To obtain ML-I crystals in complex with lactose and galactose, the sugar compound was added to the above-mentioned buffer at a concentration of 0.2 M. Crystals of ML-I complexed with lactose and galactose were obtained by hanging-drop vapour diffusion equilibrated against a reservoir consisting of saturated ammonium sulfate of varying concentrations between 30 and 40% in 0.1 M glycine±HCl buffer pH 2.5 and 0.1 M lactose or 0.2 M galactose to which 40 ml dioxane had been added. Hexagonal crystals that diffracted to 2.3 A Ê resolution were grown after $20 d at room temperature. Because of the relative high solvent content and rather large unit-cell parameters, attempts to improve the crystal quality to obtain higher resolution data and to lower the mosaic spread included an experiment in microgravity, as there is evidence that growth in microgravity can narrow mosaic spreads in protein and RNA crystals (Snell et al., 1995; Borgstahl et al., 2001 ) and a previous crystallization experiment of ML-I in complex with adenine monophosphate resulted in crystals that diffracted to 1.9 A Ê resolution. 16 crystallization trials were performed on the International Space Station (ISS) in the High Density Protein Crystal Growth (HDPCG) apparatus (previously described by Krauspenhaar et al., 2002) 
Data collection
Intensity data from crystals of ML-I in complex with lactose and galactose were collected under cryogenic conditions at 100 K using synchrotron radiation at the consortium beamline X13 (HASYLAB/ DESY), Hamburg equipped with a MAR CCD camera. The X-ray wavelength was set to 0.9073 A Ê . Both ML-I complexes belonged to the hexagonal space group P6 5 22 and diffracted to a resolution of 2.3 A Ê . The ML-I crystal in complex with lactose had unit-cell parameters a = b = 106.28, c = 312.33 A Ê , = = 90, = 120
; in the case of the galactose-complex crystal the unit-cell parameters were almost identical, with a = b = 106.83, c = 310.95 A Ê , = = 90, = 120
. Owing to the long cell axis, the oscillation range per image was set to 0.5 . The data sets were processed using DENZO and SCALEPACK (Otwinowski & Minor, 1997) . The data set of the ML-I crystal with lactose was 99.6% complete, with an R merge of 4.9%; the ML-I± galactose complex showed a completeness of 96.3%, with an R merge of 4.8%. The I/'(I) ratio in the last resolution bin was 3.7 and 2.6 for the lactose and galactose complexes, respectively. Statistics of datacollection parameters are summarized in Table 1 .
Structure solution and refinement
For the initial structure calculations and re®nement of the ML-I structures in complex with lactose and galactose, the native ML-I structure, previously re®ned to 2.3 A Ê (PDB code 1onk), was used as a starting model using the program CNS (Bru È nger et al., 1998). Rigidbody minimization was performed ®rst, followed by positional minimization and a gradual increase of the high-resolution limit from 3.2 to 2.3 A Ê . The lower limit of the data for the positional re®nement was 10 A Ê . All the re¯ections measured within these ranges were included in re®nement, with 5% of the data set reserved for R free (Bru È nger, 1992) . According to the ®t of 2F o À F c and F o À F c maps, the models were modi®ed using TURBO-FRODO (Roussel & Cambillau, 1991) running on Silicon Graphics O2 workstations. As the electron density improved at high resolution, the ligands lactose and galactose and the sugar residues of the oligosaccharide structures in the glycosylation sites were introduced into the model. As re®nement progressed, individual B factors were minimized and water molecules were added according to F o À F c maps. The ®nal re®nement statistics and the overall quality parameters of the model are presented in Table 1 .
Results
Overall fold
Mistletoe lectin I belongs to the group II carbohydrate-binding proteins, which bind their ligands in shallow preformed pockets at the protein surface (Rini, 1995) . In the case of ML-I, the galactosebinding sites form a planar array distal to the toxic A-chain (Fig. 1) . The toxic subunit has a globular fold divided into three domains according to the ricin nomenclature (Montfort et al., 1987) compromises amino acids 1±109, which contain a six-stranded parallel -sheet, an -helix and a small antiparallel -sheet. Domain II contains only -helices, ®ve of them, as secondary-structure elements, spanning amino acids 110±198. The last domain III of the A-subunit is built up of one -helix and one antiparallel -sheet through residues 199±249. The last ®ve amino acids of the A-chain are¯exible and were not visible in the electron density.
The B-chain appears to be a gene-duplication product from an ancient 40-residue galactose-binding unit (Robertus & Ready, 1984; Fig. 2) . This chain consists of two main domains each divided in four subdomains, of which three are homologous to each other. The ML-I B-chain forms a so-called -trefoil structure in which the -sheet portions of the subdomains arrange themselves around a pseudothreefold axis (Fig. 1) . In the following the architectures of galactosebinding sites I and II will be described in detail.
Galactose-binding site I
The galactose-binding site I of ML-I is formed by Asp23B, a kinked loop Asp23B-Val24B-Arg25B and by Gln36B and Lys41B (Fig. 3a) . Four key residues are involved in binding galactose via hydrogen bonds. In the centre of the binding pocket, the side chain of Asp23B is positioned via a hydrogen bond to Gln36B NE2. This orientation of Asp23B ensures establishment of hydrogen bonds to the 4 H -hydroxyl group of galactose by Asp23B OD1 as well as to the 3 H -hydroxyl group by Asp23B OD2, which form the shortest hydrogen bonds to the sugar. In addition, the 4 H -hydroxyl group of the galactose moiety hydrogen bonds to of Gln36B NE2 and 26B N. In spatial proximity to the 3 H -hydroxyl and 2 H -hydroxyl groups of galactose is Lys41B NZ, which forms hydrogen bonds to both OH groups. The latter represents a rarely noted interaction with O2 of galactose (Drickamer, 1997) . The aromatic ring of Trp38B forms the top part of the sugarbinding pocket and provides a stacking interaction with the planar galactose ring. The orientation of the tryptophan side chain is further stabilized by a hydrogen bond to a solvent molecule. The ring planes form an angle of 19.4 in the case of the ML-I±galactose complex. In the case of the ML-I±lactose complex, the galactose moiety of lactose is bound in the galactose-binding site I in the same manner as described previously for the galactose complex (Fig. 3b) . However, the angle between the plane of the aromatic ring of Trp38B and the sugar ring of lactose is 33.4
. The galactosyl part of lactose is the primary partner of interaction with the lectin; the glucosyl part remains exposed to the solvent, forming hydrogen bonds with the solvent molecules.
Galactose-binding site II
The overall architecture of galactose-binding site II (Fig. 4a) is almost identical to galactose-binding site I, although not all amino acids involved in galactose binding are conserved. The centre of the binding pocket is formed by Asp235B, which is positioned via a hydrogen bond from OD2 to of Gln257B NE2. The kinked loop consisting of the tripeptide Asp235B-Val236B-Ala237B builds up the bottom of the sugar-binding site II. The side chain of Asp235B forms a hydrogen bond from its OD1 to the 4 H -hydroxyl group of galactose and OD2 to the 3 H -hydroxyl group of the sugar. Further stabilization of the sugar±lectin complex is achieved by a hydrogen bond between Potential third galactose-binding site in ML-I located in subdomain 1. The glycerol molecule is marked in red, the aromatic amino acid Tyr79B in green, remaining residues of the pocket in blue and the water molecules in light blue. Hydrogen bonds are shown accordingly. for the ML-I±lactose complex (Fig. 4b) . In contrast to galactose-binding site I of ML-I, in site II no interactions are noted between the 2 H -hydroxyl group of the sugar moiety and the lectin.
The potential third galactose-binding site
The B-chain of type II RIP proteins is a gene-duplication product of an ancient galactose-binding subunit (Robertus & Ready, 1984) , but only two of the four subdomains retain galactose-binding capacity. The sequence alignment of galactose-binding residues and the architectures of subdomains 1 and 2 are mimicked by a similar fold in subdomain 1. However, the polar side chains required for galactose binding are changed: the central Asp is replaced by Thr66B, Met77B is in equivalent position to Gln36B of subdomain 1 and Val85B corresponds to Asn256B in 2 (Fig. 5 ). The replacement with more hydrophobic residues prevents sugar binding, although the aromatic top part of the binding pocket is conserved in that Phe79B is in an equivalent position to Trp38B in subdomain 1 and Tyr249B in 2. Interestingly, a glycerol molecule is bound in subdomain 1, mimicking the sugar compound. Glycerol is bound to the lectin via hydrogen bonds between O3 and Val85B N and Thr67B O, the latter through a bridging water molecule. Met77B, on the other hand, is not capable of participation in hydrogen bonding to the glycerol and O1 and O2 of glycerol are oriented away from this residue toward the protein surface. Obviously, this pocket lacks the ability to bind galactose as it has nonpolar residues at key positions, especially 66B (Asp to Thr) and 77B (Gln to Met), but the ability to bind the hydroxyl group effectively remains.
Discussion
ML-I has two preformed galactose-binding pockets in subdomains 1 and 2 of the B-chain; other subdomains have either lost the ability to bind galactose owing to mutations or deletion of sugar-binding residues or never developed the ability in the ®rst place. A detailed analysis of the architectures of galactose-binding sites I and II shows a strikingly similar method of sugar binding. The basic features for galactose-speci®c binding are present in both galactose-binding sites of ML-I: a central Asp, further hydrogen-bonding donors in proximity to the 4 H -and 3 H -hydroxyl group of galactose and an aromatic side chain as hydrophobic stacking partner against the sugar. Not all sugar-binding residues are conserved in subdomains 1 and 2 and the hydrogen-bonding network in binding site I is more complex than in site II, so that ML-I is an example of a lectin in which sugar-binding sites differ within one single chain.
Focusing on the central Asp, previous galactose-binding lectin structures such as those of E. corallodendron lectin (Shaanan et al., 1991) , peanut lectin (Banerjee et al., 1996) and Griffonia simplicifolia (Debaere et al., 1993) reveal that this charged amino acid is conserved and establishes the polar environment that is required for sugar binding (Rutenber & Robertus, 1991) . Its planar carbohydrate side chain achieves excellent hydrogen-bond geometry to the vicinal sugar OHs (Vyas, 1991) . The role and conformation of the Asp side chain is underlined when superimposing the galactose-binding sites I and II of ML-I with the site in ebulin (Figs. 6a and 6b) , a type II RIP with low toxic potential (Pascal et al., 2001 ). The superposition highlights a different conformation for the central Asp (Asp23B in ML-I and Asp24B in ebulin). There is a minor change in orientation of galactose in ebulin compared with ML-I, but the hydrogen bonding required for galactose binding in ebulin is conserved compared with ML-I. There is a minor difference: O3 of galactose forms a hydrogen bond with Asn46B ND2 in ebulin, whereas Lys41B provides this interaction in ML-I. In addition, a bond between O6 and Gln37B NE2, which further stabilizes the ebulin±galactose complex, is not detected in ML-I. Although nearly all amino acids in galactosebinding site II are conserved in ML-I and ebulin, the exception being that Tyr249B is changed to Phe at the top of the binding pocket, the mode of sugar binding is entirely different. The superposition of site II in ML-I and ebulin underlines the role of the Asp side chain (Fig. 6b) ; it is obvious that the side chain of Asp235B takes a different conformation in ebulin than in ML-I and is no longer the primary partner of interaction with galactose. This altered mode of galactose binding by ebulin correlates with its function as a type II RIP of low toxicity (Pascal et al., 2001) .
As lectin activity is a prerequisite for toxicity, we now compare the architecture of sugar-binding sites of ML-I and the related ricin, for which the isolated A-chains have approximately the same toxicity (Stirpe et al., 1980) . Ricin shows a similar mode of galactose binding and key features are conserved with respect to ML-I (Table 2) . However, owing to a slightly different orientation of the galactosyl part of lactose in the binding pocket, we can detect some deviations in the hydrogen-bonding pattern even though the amino acids within the pocket are conserved (Fig. 7a ). O3 and O2 of the galactosyl moiety form hydrogen bonds to Lys41B in the case of ML-I, whereas only Asn46B ND2 binds to O3 in the ricin complex. Furthermore, O6 of the galactosyl part in the ricin complex is oriented towards Gln35B NE2 and Asp25B N and makes hydrogen bonds with these residues. In contrast, O6 of the galactosyl part of lactose in ML-I is oriented toward the protein surface without contributing to hydrogen bonds in the sugar±lectin complex. The plane through the galactosyl ring of lactose forms an angle of 33 with the planar aromatic ring of Trp38B in the case of for the ricin±lactose complex. Despite uncertainties inherent in these structure determinations, it seems unlikely that angular discrepancies this large are not signi®-cant. Still, based on conservation of amino-acid sequences we would not expect a different hydrogen-bonding pattern to bind galactose in binding site I in ML-I compared with ricin. Focusing on galactosebinding site II in ML-I, the galactose-binding residues 235B, 238B and 256B are equivalent to Asp234B, Gln237B and Asn255B in ricin and the hydrogen-bonding pattern to the galactose moiety of lactose is conserved (Fig. 7b) . Orientation of the galactosyl part of lactose in both pockets and the angle formed between the planar ring of Tyr249B (248B in ricin) and the planarity through the sugar ring are nearly identical: 29 for ML-I and 26 for ricin. In contrast, in the ricin±lactose complex an additional hydrogen bond from the (a) . H -hydroxy group to of His251B NE2 stabilizes the sugar±lectin complex, whereas an equivalent interaction in ML-I cannot be performed by Thr252B. A further difference was shown in the tripeptide residues Asp234B-Val235B-Arg236B at the bottom of the ricin-binding pocket, which has the amino-acid sequence Asp-ValAla in ML-I. The impact of the loss of key hydrogen-bonding partners on the capacity for galactose binding of ricin was shown by sitedirected mutagenesis. Galactose-binding site II was identi®ed to be the high-af®nity sugar-binding site in the case of ricin (Zentz et al., 1978) . A nearly complete loss of lectin activity and thereby cytotoxicity was observed when Asn255B (Asn256B in ML-I) was mutated to alanine in galactose-binding site II (Vitetta & Yen, 1990) . Interestingly, the angles between the sugar rings and the aromatic side chains are nearly identical in galactose-binding site II in ML-I and ricin. The average angle found between the planar sugar ring and the aromatic side chain in galactose-speci®c lectins investigated so far is 32 (Kolatkar & Weiss, 1996) . Af®nity studies of ML-I and ricin show difference in af®nity for N-acetyl-d-galactosamine and d-galactose (Lee et al., 1994) . The IC 50 of ML-I against N-acetyl-d-galactosamine is 120 mM compared with 1.7 mM in the case of ricin, whereas the af®nity towards d-galactose is nearly identical: 0.9 mM for ML-I and 1.0 mM for ricin. Based on the structural determinants required for galactose binding in site I of ML-I, the N-acetyl group has a steric con¯ict with the side chain of Asp27B. For the ricin±lactose complex the N-acetyl group clashes with the side chain of Asp44B (Rutenber & Robertus, 1991) . It can be concluded that the orientation of the sugar ring in the pocket indicates a strong preference for binding galactose in ML-I site I. In contrast, the 2 H -hydroxyl group in galactose-binding site II is directed towards the protein surface and N-acetylgalactosamine can also be bound. There is also structural evidence that at the bottom of site II in ricin the polar amino acid Ser238B can provide an additional polar interaction to O7 of the N-acetyl substituent (Fig. 8a) . In contrast to ricin, ML-I has an alanine in this position, which is not capable of making a contribution in order to stabilize the complex (Fig. 8b) . Of course, there may still be unrecognized determinants involved in binding N-acetyl-d-galactosamine that are needed to explain fully the signi®cant difference in af®nities of ML-I and ricin.
The af®nity of ML-I towards galactose and lactose is not only conditioned by the architecture of the binding sites, because recombinant MLB possesses reduced af®nity against monosaccharides (Eck et al., 1999) . Thus, it becomes clear that not only the mode of galactose binding but also the type of glycosylation has an in¯uence on af®nity and consequently on the toxic potential, as oligosaccharide side chains are known to be essential for stability and recognition. This phenomenon was also shown for the recombinant ricin B-chain (Wales et al., 1991) .
The toxicity of RIPs is based on the ef®ciency of uptake into target cells. Differences in this ef®ciency confer differences between ML-I and ricin in speci®city against complex galactose-terminated oligosaccharide structures on cell membranes and in speci®city against the type and quantity of cell receptors on target cells. As discussed and shown before, the speci®city towards monosacharides is nearly identical. While the detailed comparison of galactose binding of ML-I and other sugar-complexed RIP structures with high and low toxic potential underline the overall impact of lectin activity on toxicity, RIP toxicity remains an activity in¯uenced by many variables.
Based on the mode of galactose binding of ML-I in subdomains 1 and 2, essential and conserved residues responsible for galactose binding as well as variable residues are outlined. These observations show the evidence that site-directed mutagenesis experiments replacing Thr66B by Asp and Met77B by Gln would most probably succeed in restoring the ability to bind galactose in subdomain 1. A third galactose-binding site would be expected to increase the sugarbinding capacity. This aspect is of importance in terms of the design studies of the antitumoral drug rViscumin, which is currently under investigation in phase I clinical studies and for which phase II studies are being considered. Further attempts may also succeed to engineer novel sugar speci®cities into ML-I that will bring MLB in focus as a potential transport molecule for pharmaceuticals and for ef®cient uptake in targeted cell types.
